SCHEMBL18409692

SCHEMBL18409692

Oc1ccc(-c2nc(CCc3c[nH]c4ccccc34)oc2-c2ccc(O)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.53
DRD2 P14416 2/20 0.53
HTR2A P28223 2/20 0.53
HTR1A P08908 1/20 0.53
HTR7 P34969 1/20 0.53
PTPN1 P18031 1/20 0.48
PDE10A Q9Y233 1/20 0.45
LMNA P02545 2/20 0.44
RXRA P19793 7/20 0.44
RXRB P28702 7/20 0.44
NR4A2 P43354 5/20 0.44
RXRG P48443 4/20 0.44
KDM4E B2RXH2 1/20 0.44
ABCC4 O15439 1/20 0.44
C5 P01031 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 1/20 0.44
CHRM1 P11229 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409331 0.90 PDE10A (0.54) HTR6DRD2HTR2AHTR1AHTR7
SCHEMBL18409678 0.89 PTPN1 (0.57) HTR6DRD2HTR2AHTR1AHTR7
SCHEMBL18409685 0.85 PTPN1 (0.46) HTR6DRD2HTR2AHTR1AHTR7
SCHEMBL18409335 0.85 GPR84 (0.56) LMNARAB9A
SCHEMBL18409686 0.85 TRPV1 (0.47) PDE10ALMNARXRARXRBNR4A2
SCHEMBL18409642 0.83 NR4A2 (0.53) HTR6DRD2HTR2AHTR1AHTR7
SCHEMBL18409683 0.82 GPR84 (0.58) PTPN1RAB9AALDH1A1
SCHEMBL18409677 0.82 GPR84 (0.58) PTPN1RAB9AALDH1A1
SCHEMBL18409639 0.82 GPR84 (0.52) HTR1ARXRARXRBNR4A2RXRG
SCHEMBL22692981 0.81 NR4A2 (0.46) HTR6DRD2HTR2AHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 HTR6 4055/4885DRD2 4797/4885HTR2A 4576/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 HTR6 4248/4885DRD2 4672/4885HTR2A 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.